Sorry, you need to enable JavaScript to visit this website.

Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European Commission

NEW YORK AND MAINZ, GERMANY, May 13, 2022Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced they have reached an agreement with the European Commission (EC) to amend their originally agreed contractual delivery schedules for the Pfizer-BioNTech COVID-19 Vaccine.

Annaliesa Anderson, Ph.D., Will Lead Pfizer’s Vaccine Research & Development 

•    Effective August 1, Annaliesa Anderson will succeed Kathrin Jansen, who previously announced her retirement from Pfizer

NEW YORK, June 1, 2022 — Pfizer Inc. (NYSE: PFE) today announced that Annaliesa Anderson, Ph.D., has been appointed Senior Vice President and Head of the Company’s Vaccine Research & Development (R&D) organization effective August 1, succeeding Kathrin U. Jansen, Ph.D., who will be retiring from Pfizer. 

Subscribe to Updates